Compare Nu Holdings Ltd (NU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Nu Holdings LtdTrade

Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Nu Holdings Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Nu Holdings Ltd trades at $14.39 (market cap $67.58B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.

	NU	VRTX
Market Cap	$67.58B	$121.95B
Sector	Financials	Health
52-Week High	$18.76	$529.59
52-Week Low	$11.60	$366.54
Enterprise Value	—	$116.69B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

OpenAI adds financial leaders Vélez and Vince to boards ahead of potential IPO.CNBC · 4 hours agoBullish View details →

VRTX

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 12 hours agoNeutral View details →

About Nu Holdings Ltd

Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.